Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Lung Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Chordoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Malignancies 1 Advanced Liver Cancers 1

Interventions

pembrolizumab 14 Cisplatin 13 Specimen Handling 11 Magnetic Resonance Spectroscopy 7 Brachytherapy 7 Bevacizumab 7 Radiotherapy 6 atezolizumab 5 Platinum 5 Paclitaxel 5 Nivolumab 5 Human Papillomavirus DNA Tests 5 Gemcitabine 5 Colposcopy 5 Carboplatin 5 Blood Specimen Collection 5 Radiation 4 Fulvestrant 4 lenvatinib 3 Surveys and Questionnaires 3 Radiation Dose Hypofractionation 3 Drug Therapy 3 Biopsy 3 1,2-diaminocyclohexaneplatinum II citrate 3 zimberelimab 2 tisotumab vedotin 2 spartalizumab 2 palbociclib 2 camrelizumab 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uterine Cervical Neoplasms × Tiragolumab × 90 days × Clear all

NCT04300647 2026-03-12

SKYSCRAPER-04

Hoffmann-La Roche

Phase 2 Completed

172 enrolled 27 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡